In a bid to broaden its immuno-oncology franchise, Ipsen Pharma has entered into a multi-year collaboration agreement with Marengo Therapeutics to develop and commercialise two precision immuno-oncology compounds leveraging the latter’s Selective T Cell Activation Repertoire (STAR) platform. As per the deal, which is worth up to US$1.6 B, Marengo will be responsible for preclinical development and IND clearance, after which Ipsen will pick up responsibility for the programme’s clinical development and commercialisation. The deal aligns with Ipsen’s growth strategy, as it focuses onexternal innovations through partnerships.